Short-term semaglutide disruption unlikely to dent Dr Reddy’s growth plans: Systematix
Dr Reddy’s Laboratories’ growth outlook from its semaglutide opportunity remains largely intact, provided the company resolves its recently disclosed supply issues within the next month, according to Vishal Manchanda, Pharma Analyst at Systematix Group. “If they kind of get this done in the next one month, that should not meaningfully impact expectations that people have…
